Akorn, Inc. (NASDAQ:AKRX)

CAPS Rating: 3 out of 5

The Company manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others.

Results 1 - 20 of 28 : 1 2 Next »

Recs

0
Member Avatar joe56680 (< 20) Submitted: 4/21/2015 3:52:58 PM : Outperform Start Price: $55.39 AKRX Score: -22.75

IBD Top Sector Performer

Recs

0
Member Avatar ScalaAnalyst (21.61) Submitted: 3/17/2015 11:44:29 AM : Outperform Start Price: $43.84 AKRX Score: -0.93

20150317
Akorn, Inc (AKRX) has fallen from it's most recent month from it's high of 55.86/sh. Although this company is trading today with a high PE of 112.63, It may be worth looking into.

The professional analysts have been moving their estimates upwards every other week. Also, the companies own insiders have decided to increase their holdings of this company. Currently insiders hold 23.88% of the company. You know these guys will be doing everything to protect their investment.

I'm not much for phara companies as I understand they have a lot of R & D and this is expensive. Also, they must seek approval of their products from the FDA before moving it to market. These guys maufacture medications that are basically generic. Not a lot of new products. Most of the products they market through their channels are tried and true products that hospitals know and trust. Most of their products are manufactured for the diagnostic and therapeutic ophthalmic pharmaceuticals.

Anyway, their earnings seem to constantly growing, along with their sales. Their quarterly revenue growth is an outstanding 168%.

Currently they are at a recent low and I believe they will continue to grow. Granted at this PE it is a little over priced, but good quality comes with a good price. I'm thinking this will become a good long investment ride.

Recs

0
Member Avatar Kidkerner (45.84) Submitted: 1/23/2015 7:16:19 PM : Outperform Start Price: $42.73 AKRX Score: -2.09

Massive growth.

Recs

0
Member Avatar PunktBewiesen (71.37) Submitted: 11/6/2014 9:39:43 PM : Outperform Start Price: $36.36 AKRX Score: +14.80

Oversold 11.05.14

Recs

0
Member Avatar racoveanul (84.91) Submitted: 4/12/2014 3:33:34 PM : Outperform Start Price: $21.77 AKRX Score: +82.76

My 1y target for Akorn, Inc. (Symbol: AKRX) is $ 26.63. It implies an increase of 23.68% of the share price (April 11 2014).

Recs

0
Member Avatar TerryFool (75.21) Submitted: 3/10/2014 8:38:49 PM : Outperform Start Price: $21.99 AKRX Score: +82.72

EPS 1YR 40% 2YR 35% 5YR 20%

Recs

0
Member Avatar tedski2000 (< 20) Submitted: 10/29/2013 2:19:00 PM : Outperform Start Price: $20.85 AKRX Score: +87.59

This stock was on the Zacks list of #1 Rank Additions on the day it was placed in the CAPS portfolio.

Recs

0
Member Avatar rknapton (< 20) Submitted: 7/23/2013 8:12:18 PM : Outperform Start Price: $13.53 AKRX Score: +194.42

Long. Pharma. PE 34x ttm 17x fye. $1.3B mkt cap. 42% Rev growth, 248% E growth.

Recs

0
Member Avatar claricecliff (< 20) Submitted: 8/6/2012 12:44:01 PM : Outperform Start Price: $13.65 AKRX Score: +165.38

I don't think the analysts are aware of the scope of the generic market. Some are saying (Deutsche) that Akorn will not manufacture enough generics? How do they know when the FDA is not working with DEA to know what's in the pipeline or which drugs will be approved?

Recs

0
Member Avatar cobradon (98.99) Submitted: 2/1/2012 6:05:44 PM : Outperform Start Price: $3.32 AKRX Score: +1,099.11

I saw one of the rating agencies tout this as a raging buy.... But, beyond that I like the whole pharma section as the baby boomers become in need.

Recs

0
Member Avatar modestus1 (< 20) Submitted: 11/1/2011 11:59:33 PM : Outperform Start Price: $9.93 AKRX Score: +263.83

generics

Recs

0
Member Avatar Liquidman21 (< 20) Submitted: 9/25/2011 2:20:52 AM : Outperform Start Price: $8.13 AKRX Score: +348.58

Generic alternative drugs are the future. This is a sure fire pick!

Recs

0
Member Avatar kdzfool (< 20) Submitted: 9/24/2011 1:11:05 AM : Outperform Start Price: $9.07 AKRX Score: +291.29



Feel management is getting all cylinders operating properly. Paying more attention to details in compliance with fda and atf watchdogs, obtaining more profitable products and being the sole supplier of some, while controling dept properly.

Recs

0
Member Avatar elcheapo2020 (61.66) Submitted: 9/22/2011 12:57:04 PM : Outperform Start Price: $7.82 AKRX Score: +366.90

This company is currently experiencing high returns, high margins, a reasonable P/E, low debt, and good revenue growth. Today the market is getting slammed and is down around 400 points, and even though this stock has pulled back slightly today, it looks as if the market is dragging it down, not it's fundamentals.

This stock is a very long buy, particularly because of the way it's holding up today vs. the rest of the market. Very resistent on a bad down day. Right now it's under $9/share, but give it another year or two, and it'll be in the mid to upper teens, provided the numbers remain constant.

If not buying, at least add it to your watched list.

Recs

0
Member Avatar umeng78 (< 20) Submitted: 5/18/2011 11:33:19 PM : Outperform Start Price: $6.94 AKRX Score: +464.68

new high

Recs

2
Member Avatar HealthcareGuy (99.68) Submitted: 12/29/2010 4:44:02 PM : Outperform Start Price: $5.39 AKRX Score: +621.89

Akorn, is a generic pharma company that has been remade by successful healthcare turnaround investor John Kapoor (Chariman of the Board). The major catalyst for this name, will be FDA approval of AKRX’s generic version of Vancocin (first to file, been in FDA limbo for many years). Even branded Vanco manufacturer, Viropharma, has hinted that they believe 2011 will be the year they finally lose their vanco monopoly, which will probably send AKRX to the $12 range (assuming they receive a 6 month exclusivity)

Recs

0
Member Avatar RXDOC73 (99.48) Submitted: 12/16/2010 8:16:41 AM : Outperform Start Price: $6.04 AKRX Score: +543.85

Small and growing stronger

Recs

0
Member Avatar yoyoguy (< 20) Submitted: 6/8/2010 6:25:34 PM : Outperform Start Price: $2.85 AKRX Score: +1,315.74

Good looking upward market trend, despite occasional falls during market frenzies.

Recs

0
Member Avatar JOSEFB (< 20) Submitted: 5/5/2010 12:34:42 PM : Outperform Start Price: $2.84 AKRX Score: +1,339.78

Great cash position and products

Recs

0
Member Avatar Cruzera (< 20) Submitted: 4/21/2010 9:34:23 PM : Outperform Start Price: $2.05 AKRX Score: +1,926.52

The market has had a good run and investers are looking for innovation. Medical breakouts are a good place to hunt for cheap stocks. Acorn will continue to out do the market.

Results 1 - 20 of 28 : 1 2 Next »

Featured Broker Partners


Advertisement